OvagenvsTestagen

Molecular Formula

C₁₅H₂₅N₃O₈

Molecular Weight

375.4 g/mol

Half-Life

Short plasma half-life typical of tripeptides; biological effects persist for weeks through epigenetic modifications to hepatic gene expression; metabolized to constituent amino acids (glutamic acid, aspartic acid, leucine)

Bioavailability

Effective via oral capsule (10 mg twice daily), sublingual liquid (0.1 mg/mL), and subcutaneous injection routes; penetrates cell membranes and nuclear membranes as a cell-penetrating peptide; tissue-specific activity demonstrated in organotypic hepatic cultures at 10⁻⁶ to 10⁻⁹ M

CAS Number

Not assigned (proprietary Khavinson peptide)

Molecular Formula

C₁₇H₂₉N₅O₉

Molecular Weight

447.4 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to testicular gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to short tetrapeptide structure

CAS Number

Not publicly registered

Common

• Mild digestive discomfort
• Mild fatigue
• Mild headache
• Minor appetite changes

Uncommon

• Mild nausea

Serious

• No documented serious adverse effects

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Libido fluctuation

Uncommon

• Mild acne or skin oiliness

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies. As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users. Reproductive safety in animal models shows normal fetal development with no teratogenicity.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xSevere glutamic acid metabolism disorders (extremely rare)
• xActive autoimmune hepatitis in flare without physician supervision

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Testagen (lyophilized peptide complex) lacks published human safety data—all information derives from unpublished manufacturer data and theoretical extrapolation from rat studies. As an androgen secretagogue, it carries class risks including erythrocytosis (elevated red blood cell count), liver enzyme elevation, lipid profile unfavorable changes (reduced HDL, increased LDL), and prostate-related effects including urinary obstruction and potential malignancy acceleration. Cardiovascular risk including hypertension and increased thrombotic events are theoretical concerns based on androgen class pharmacology.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, glycine)
• xHormone-sensitive cancers (prostate, testicular) — potential stimulation of androgen-dependent pathways
• xPregnancy and breastfeeding (female partners) — not applicable for direct use but consider reproductive implications
• xSevere hepatic or renal impairment — peptide metabolism may be altered